Farabi Pharma's Six-Month Profit Passed Its Whole Prior Year, but Operating Cash Is 37.6% of Profit; Entry Holds Up to 21,273 Rial (Monday 2 November 2026)
Sahmino Research Desk | 2 November 2026 | Short | 00:47
Watch onSahmino
Farabi Pharmaceutical's standalone net profit for the six months to 22 September 2026 reached 16,341 billion rial, 5.8 times a year earlier and above all of fiscal 1404; but operating cash was 37.6% of profit and receivables rose 53%. Close on 1 November: 21,050 rial, P/E 6.58 against 10.53 for the industry. Sahmino desk: target 22,373…
Related videos
SHHZ's six-month operating cash covered 2.6% of profit versus 89.5% on a restated trailing year; Sahmino's invalidation is 3,080 rials (November 1, 2026)
Short | 00:47StocksDabid Under the Microscope: Dr Abidi Pharmaceutical's Six-Month Profit Jumped 3.3x; Dissecting a Surge That Didn't Come From Sales Alone (Saturday, 18 July 2026)
Short | 01:27StocksNGFO six-month profit rose 10.2-fold and P/E of 5.12 is below half its sector, but October scrap rose 27% versus 14% for sheet; Sahmino target 14,014 rials (November 3, 2026)
Short | 00:50StocksKRSH Stands 17.7% Below Its 4 October High as Half-Year Profit Rises 3.8x but Latest Monthly Sales Fall 8.3% (4 November 2026)
Short | 00:46Stocks
